Molbio Diagnostics Targets ₹940 Crore Through IPO for Expansion

Molbio Diagnostics, a key player in the molecular diagnostics sector, has announced plans to raise ₹940 crore through an initial public offering (IPO). This move is designed to fund the company’s capital expenditures and reduce promoter stakes, potentially attracting high-risk investors seeking long-term growth opportunities.

Capital Expansion and Stake Reduction

The company aims to generate ₹200 crore from a fresh issue of shares, earmarked for enhancing its capital expenditures. Additionally, an offer for sale is expected to bring in ₹740 crore, reducing the promoter group's stake from 46.6% to 43%. This strategic move comes as Molbio seeks to bolster its financial foundation and expand its global reach.

Operating six manufacturing facilities across India, Molbio Diagnostics serves a diverse clientele in over 90 countries, including government health programs, diagnostic laboratories, hospitals, and international healthcare organizations. The company has experienced significant revenue growth, largely due to its tuberculosis diagnostic test kits, a major contributor to its income.

Financial Performance and Market Prospects

Founded in 2000, Molbio Diagnostics specializes in developing diagnostic solutions for both infectious and non-communicable diseases. It has developed the 'Truenat' platform, a portable diagnostic system designed to deliver accurate test results in under an hour, ideal for resource-limited settings. This platform supports molecular testing for over 30 diseases through 43 diagnostic assays and additional services in radiology and digital pathology.

Financially, the company reported a 31.5% annual increase in revenue from operations, reaching ₹1,445.7 crore, with net profits rising by 40.2% to ₹164.1 crore between FY24 and FY26. The EBITDA margin improved to 22.6% in FY26 from 22% in FY24. On a year-on-year basis, FY26 saw a 41.7% revenue jump, a 27.9% increase in EBITDA, and an 18.4% rise in net profit.

Valuation and Investor Considerations

Post-IPO, Molbio Diagnostics seeks a price-earnings (P/E) multiple of up to 57, reflecting confidence in its market position despite lacking directly comparable listed peers in India. Other companies in the healthcare diagnostics and medical device sector, such as Poly Medicure, Dr. Lal PathLabs, Metropolis Healthcare, and Vijaya Diagnostic Centre, show P/E multiples ranging from 54 to 81.

Given these financial metrics and market strategies, Molbio Diagnostics presents a potentially lucrative opportunity for investors with a high-risk tolerance, looking for substantial returns in the diagnostics industry.